Stay Informed on Corporate Sustainability
Explore industry news, insights, and updates from the Pharma Industry Awards.
Eli Lilly commits $500 million to South Korea biopharma innovation
United States-based Eli Lilly has pledged $500 million (€423 million) over five years to South Korea's biopharma industry. The investment strengthens pharmaceutical manufacturing excellence capabilities through clinical trials and an innovation incubator.
Alnylam Pharmaceuticals signs $1.23 billion cardiovascular collaboration with Tenaya Therapeutics
United States-based Alnylam Pharmaceuticals has signed a discovery collaboration worth up to $1.23 billion (€1.06 billion) with cardiovascular disease specialist Tenaya Therapeutics. The partnership strengthens pharmaceutical manufacturing excellence capabilities for heart disease therapies.
Thermo Fisher Scientific opens distribution centre in County Meath
United States-based Thermo Fisher Scientific has opened a 70,000-square-foot distribution centre in Bracetown, County Meath, expanding Ireland's pharmaceutical manufacturing excellence infrastructure. The facility increases in-country distribution capacity by over 400 per cent.
Chanelle Pharma partners with SAP to modernise global manufacturing operations
County Galway-based Chanelle Pharma has partnered with SAP to implement SAP S/4HANA Cloud and SAP Business AI. The initiative modernises pharmaceutical manufacturing excellence operations across Ireland, Britain, Portugal and Jordan to accelerate global growth.
Finalists announced for Women in Pharma Awards 2026
The Women in Pharma Awards 2026 has unveiled its shortlist, marking a significant milestone in Ireland's pharmaceutical calendar. In its second year, the programme has established itself as the country's premier platform for honouring women's contributions to excellence, innovation, and leadership across the life sciences. Categories span the full spectrum of the industry, from Best Female Led Team and Excellence in Senior Leadership across pharma, life sciences, and contract services to Rising Star of the Year and Workplace of the Year, reflecting the breadth of achievement driving sector progress. The awards also include specialised categories for leadership in clinical operations, education and mentoring, supply chain and logistics, engineering and manufacturing, finance, HR, marketing and communications, quality, sales and commercial, and site leadership, alongside two special honours: the Overall Leader Award and the Legacy Award, which will both be announced at the ceremony.
Asahi Kasei to acquire Aicuris to strengthen infectious disease pharmaceutical platform
Asahi Kasei will acquire biopharmaceutical company Aicuris for approximately €780 million ($919 million). The transaction expands Asahi Kasei's pharmaceutical manufacturing excellence platform into severe infectious diseases for immunocompromised patients.
Eton Pharmaceuticals acquires HEMANGEOL commercialisation rights for rare disease expansion
Eton Pharmaceuticals has acquired commercialisation rights to HEMANGEOL oral solution for infantile hemangioma treatment. The transaction expands Eton's rare disease portfolio to ten commercial products and strengthens pharmaceutical manufacturing excellence capabilities.
Zymeworks secures $250 million royalty financing from Royalty Pharma
Zymeworks has secured $250 million (€212 million) in royalty-backed financing from Royalty Pharma to strengthen its balance sheet. The transaction supports pharmaceutical manufacturing excellence operations and provides capital for strategic acquisitions through 2028.
Novo Nordisk submits Wegovy reimbursement request to Irish health service
Novo Nordisk has submitted a full reimbursement application to Ireland's Health Service Executive for obesity drug Wegovy. The assessment process strengthens pharmaceutical manufacturing excellence sector engagement with national healthcare systems and patient access frameworks.
Chanelle Pharma reports 51.5 per cent profit growth in manufacturing operations
County Galway-based Chanelle Pharma reported pretax profits increasing 51.5 per cent to €16.75 million as revenues rose 17 per cent to €223.19 million. The performance strengthens Ireland's position in generic pharmaceutical manufacturing excellence.
Discover What's Happening
Explore our newsletters
Join our Newsletter to receive the latest industry trends, expert tips, and exclusive insights delivered straight to your inbox!

Sort by


.png)

